<DOC>
	<DOC>NCT00070707</DOC>
	<brief_summary>An association between seasonal allergic rhinitis (SAR) and allergic asthma has been established through epidemiologic, pathophysiologic, and therapeutic studies. This study will compare Nasonex Nasal Spray to Placebo in treating the nasal and asthma symptoms experienced by subjects with SAR and concomitant asthma.</brief_summary>
	<brief_title>Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Eligibility Criteria: Subject must have at least a twoyear history of seasonal allergic rhinitis and of increase asthma symptoms associated with the allergy season under study. FEV 1 70% of predicted at both Screening and Baseline visits. Subject must demonstrate an increase in absolute FEV 1 less then 12%, with an absolute volume increase of at least 200 ml, after reversibility testing at Screening or within the past 12 months. Subjects must be skin test positive (skin prick test with a wheal diameter at least 3mm larger than the diluent control or intradermal testing with the wheal diameter at least 7 mm larger than diluent control) at screening, or within 12 months prior to the screening visit, to a seasonal allergen (which may include seasonal molds) prevalent during the study period. Subjects with asthma who require chronic use of inhaled or systemic corticosteroids. Subjects who are morbidly obese (BMI&gt;35)</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Concomitant Asthma</keyword>
</DOC>